Caris Life Sciences (CAI) officer awarded 63,971 restricted stock units

Rhea-AI Filing Summary

Denton John Russel reported acquisition or exercise transactions in this Form 4 filing.

Caris Life Sciences, Inc. officer John Russel Denton received a grant of 63,971 shares of Common Stock on March 6, 2026, reported as restricted stock units that will vest under the applicable grant agreement. Following this grant, he holds 187,562 shares directly and 9,184 shares indirectly through a trust.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Denton John Russel

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	63,971	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 187,562 shares (Direct); Common Stock — 9,184 shares (Indirect, By Trust)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Denton John Russel

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TX 75039

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		A		63,971(1)	A	$0	187,562	D
Common Stock								9,184	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Remarks:

Senior Vice President, General Counsel, and Secretary

	/s/ J. Russel Denton	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Caris Life Sciences (CAI) report for John Russel Denton?

Caris Life Sciences reported that officer John Russel Denton received a grant of 63,971 shares of Common Stock as restricted stock units on March 6, 2026. These units vest according to the related grant agreement, reflecting equity-based compensation rather than an open-market share purchase.

How many Caris Life Sciences (CAI) shares does John Russel Denton hold after this Form 4?

After the reported grant, John Russel Denton holds 187,562 shares of Caris Life Sciences Common Stock directly. He also has 9,184 additional shares reported as held indirectly by a trust, giving a clearer picture of his combined direct and indirect equity position.

Was the Caris Life Sciences (CAI) Form 4 transaction an open-market buy or a compensation grant?

The Form 4 shows a compensation-related grant coded as an acquisition (A), not an open-market purchase. Denton received 63,971 restricted stock units at a reported price of $0.000 per share, which will vest over time under a specific grant agreement.

What does the restricted stock unit footnote mean in the Caris Life Sciences (CAI) Form 4?

The footnote explains that the 63,971 reported shares represent an award of restricted stock units. These units vest in accordance with the applicable grant agreement, meaning Denton’s ability to fully own or transfer the underlying shares depends on meeting those vesting conditions.

How is trust ownership reported for Caris Life Sciences (CAI) insider John Russel Denton?

The filing lists 9,184 shares of Common Stock as held indirectly “By Trust.” This indicates ownership through a trust rather than in Denton’s name directly, and it is classified separately from his 187,562 directly held shares in the post-transaction holdings table.